Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06183645 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility.

Study acronym: ActiCIDP
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revisedv3
  2. Lead sponsor: Dr. Stéphanie Delstanche to Centre Hospitalier Universitaire de Liege
    • Collaborators revised (2)
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ActiCIDP is a monocentric academic study. Patients with Chronic inflammatory demyelinating polyradiculoneuritis may be included on a voluntary basis. The investigators plan to include a group of approximately 40 patients with CIDP. The investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.
Trial Details
NCT Number NCT06183645
Lead Sponsor Centre Hospitalier Universitaire de Liege
Collaborators: SYSNAV, Centre Hospitalier Régional de la Citadelle
Conditions
(from sponsor)		 Chronic Inflammatory Demyelinating Polyneuropathy
Related terms Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov